Streetbeat News

Analyst Ratings

RIVN

Rivian Automotive (NASDAQ:RIVN) has received mixed analyst ratings over the last three months, with a current average 12-month price target of $20.14, down 19.98% from the previous $25.17. Analysts from firms including Barclays, Goldman Sachs, Needham, Deutsche Bank, and Stifel have adjusted their ratings and price targets, reflecting diverse perspectives on the company's performance and market standing. Rivian's financial indicators show a significant revenue growth rate of 149.44% as of September 30, 2023, but challenges in net margin, ROE, and ROA. The company's market capitalization and debt management are also highlighted.

Portfolio Pulse from Benzinga Insights

February 12, 2024 | 12:00 pm

LOW

JP Morgan analyst Christopher Horvers upgraded Lowe's Companies (NYSE:LOW) from Neutral to Overweight and increased the price target from $210 to $265.

Portfolio Pulse from Benzinga Newsdesk

February 12, 2024 | 11:58 am

PEP

Citigroup analyst Filippo Falorni upgraded PepsiCo (NASDAQ:PEP) from Neutral to Buy and increased the price target from $180 to $195.

Portfolio Pulse from Benzinga Newsdesk

February 12, 2024 | 11:48 am

WTW

BMO Capital analyst Michael Zaremski upgraded Willis Towers Watson (NASDAQ:WTW) from Underperform to Market Perform and set a price target of $298. This upgrade reflects a positive shift in BMO Capital's outlook on WTW's stock.

Portfolio Pulse from Benzinga Newsdesk

February 12, 2024 | 11:46 am

TNGX

Piper Sandler analyst Joseph Catanzaro has initiated coverage on Tango Therapeutics (NASDAQ:TNGX) with an Overweight rating and set a price target of $18. This indicates a positive outlook on the stock's future performance.

Portfolio Pulse from Benzinga Newsdesk

February 12, 2024 | 11:43 am

AUTL

Needham analyst Gil Blum maintains a Buy rating on Autolus Therapeutics (NASDAQ:AUTL) and raises the price target from $8 to $9.

Portfolio Pulse from Benzinga Newsdesk

February 12, 2024 | 11:34 am

DAY

Needham analyst Scott Berg reiterates a Buy rating on Dayforce (NYSE:DAY) and maintains an $82 price target.

Portfolio Pulse from Benzinga Newsdesk

February 12, 2024 | 11:33 am

COGT

Needham analyst Ami Fadia reiterated a Buy rating on Cogent Biosciences (NASDAQ:COGT) and maintained a $15 price target.

Portfolio Pulse from Benzinga Newsdesk

February 12, 2024 | 11:31 am

SBOW

Roth MKM analyst Leo Mariani initiates coverage on SilverBow Resources (SBOW) with a Buy rating and a price target of $41.

Portfolio Pulse from Benzinga Newsdesk

February 12, 2024 | 11:10 am

PSBD

RBC Capital analyst Kenneth Lee initiates coverage on Palmer Square Capital BDC (NYSE:PSBD) with an Outperform rating and a price target of $17.

Portfolio Pulse from Benzinga Newsdesk

February 12, 2024 | 11:06 am